OraSure Technologies Inc.

Company Overview

OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries, DNA Genotek, Diversigen and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The company reported revenue of $171.1 million in 2020. Under the diagnostics and testing business segment, the company has rapid diagnostics for HIV, Hepatitis C, COVID-19 and Ebola, as well as oral fluid laboratory tests for detecting various drugs of abuse.

OraSure Technologies is a global leader in infectious disease diagnostics. In July 2017, the company’s OraQuick HIV Self-Test (HIVST) received WHO prequalification.

Financial Highlights (FY 2024)

Company's Business Segments

• Products and Services : This segment includes solutions for HIV, Sample Management Solutions, COVID-19, HCV, Risk Assessment Testing, Other product and services revenues, Molecular Services.
• Other : This segment includes Captial gains and other revenue.